PTC Therapeutics (PTCT) to Release Quarterly Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is set to issue its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.31) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.53). The business had revenue of $307.06 million for the quarter, compared to analyst estimates of $315.90 million. On average, analysts expect PTC Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

PTC Therapeutics Stock Performance

PTCT stock opened at $25.41 on Wednesday. PTC Therapeutics has a one year low of $17.53 and a one year high of $59.84. The company’s fifty day moving average price is $28.10 and its 200-day moving average price is $25.74. The company has a market capitalization of $1.95 billion, a PE ratio of -3.04 and a beta of 0.67.

Insider Buying and Selling at PTC Therapeutics

In other news, CEO Matthew B. Klein sold 3,361 shares of the stock in a transaction on Friday, April 19th. The shares were sold at an average price of $24.89, for a total value of $83,655.29. Following the sale, the chief executive officer now owns 225,807 shares of the company’s stock, valued at $5,620,336.23. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 6,404 shares of company stock worth $165,506 over the last 90 days. 5.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PTCT shares. Royal Bank of Canada boosted their target price on shares of PTC Therapeutics from $22.00 to $28.00 and gave the stock a “sector perform” rating in a report on Friday, March 1st. TD Cowen lowered their target price on shares of PTC Therapeutics from $32.00 to $30.00 and set a “market perform” rating on the stock in a report on Friday, March 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of PTC Therapeutics in a report on Friday, April 12th. Finally, Jefferies Financial Group boosted their target price on shares of PTC Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Five research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, PTC Therapeutics has a consensus rating of “Hold” and an average target price of $33.53.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.